CSI Market
Sign In | Register

Adaptive Biotechnologies (ADPT) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access ADPT Annual Cash Flow →
Cash flow data covering Adaptive Biotechnologies–Jun 30 2025 offers a view into how Jun 30 2026's cash position has developed alongside business activity.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jun 30 2026)
6 Months 		(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Operating Activities
Income-59.96
Depreciation & amortization6.69
Amortization of Other Assets0.84
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.76
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment0.00
Share-based Compensation23.05
Income (Loss) from Equity Method Investments0.00
Fair Value Adjustment of Warrants0.00
Health Care Organization Patient Service Revenue Provision for Bad Debts-
Increase Decrease In Other Receivables And Other Current Assets1.45
Increase Decrease In Deferred Rent Credit Noncurrent-
Income taxes0.00
Gain (Loss) on Sale of Derivatives0.00
Increase (Decrease) in Accounts Receivable-0.85
Increase (Decrease) in Accounts Payable and Accrued Liabilities-6.50
Accrued Expense0.00
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets2.53
Other Working Capital0.20
Other Noncash Income (Expense)0.11
Other net0.11
Payments for (Proceeds from) Other Operating Activities17.09
Discontinued operations0.00
Net Cash flow from Operating Activities-15.94
Investing Activities
Capital Expenditures-1.98
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Marketable Securities89.23
Payments to Acquire Marketable Securities-121.59
Real Estate Investments0.00
Increase (Decrease) in Restricted Cash0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-34.33
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings335.51
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock-12.12
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Increase (Decrease) in Deposits Outstanding0.00
Other financing activities net0.00
Other net-173.71
Proceeds From Contribution Of Original Owners-
Payments To Terminate Interest Rate Swap-
Payment Of Tax Distribution To Unit Holders-
Stock Withheld During Period Value Restricted Stock-
Payment Of Tax Distribution To Unit Holders Cash Flow Impact-
Stock Forfeited On Vesting Restricted Stock-
Payments To Repurchase Limited Liability Company Units-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities149.69
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-17.92
Total Cash Flow99.42
4 historic quarters locked

Sign in to unlock the full Adaptive Biotechnologies cash flow history.

Sign In Create Free Account

About Adaptive Biotechnologies Corp Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001193125-26-332940

Figures are derived from filed reports and may be restated. Historical data is subject to revision.